Abstract
Background Antimicrobial resistance (AMR) is a complex multifactorial outcome of health, socio-economic and geopolitical factors. Therefore, tailored solutions for mitigation strategies could be more effective in dealing with this challenge. Knowledge-synthesis and actionable models learned upon large datasets are critical in order to diffuse the risk of entering into a post-antimicrobial era.
Objective This work is focused on learning Global determinants of AMR and predicting the susceptibility of antibiotics at the isolate level (Local) for WHO (world health organization) declared critically important pathogens Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, Enterobacter cloacae, Staphylococcus aureus.
Methods In this study, we used longitudinal data (2004-2017) of AMR having 633820 isolates from 70 Middle and High-income countries. We integrated AMR data with the Global burden of disease (GBD), Governance (WGI), and Finance data sets in order to find the unbiased and actionable determinants of AMR. We chose a Bayesian Decision Network (BDN) approach within the causal modeling framework to quantify determinants of AMR. Finally Integrating Bayesian networks with classical machine learning approaches lead to effective modeling of the level of AMR.
Results From MAR (Multiple Antibiotic Resistance) scores, we found that developing countries are at higher risk of AMR compared to developed countries, for all the critically important pathogens. Also, Principal Components Analysis(PCA) revealed that governance, finance, and disease burden variables have a strong association with AMR. We further quantified the impact of determinants in a probabilistic way and observed that health system access and government effectiveness are strong actionable factors in reducing AMR, which was in turn confirmed by what-if analysis. Finally, our supervised machine learning models have shown decent performance, with the highest on Staphylococcus aureus. For Staphylococcus aureus, our model predicted susceptibility to Ceftaroline and Oxacillin with the highest AUROC, 0.94(with SE of 0.01%) and 0.89(with SE of 0.002%) respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by the Wellcome Trust/DBT India Alliance Fellowship IA/CPHE/14/1/501504 awarded to Tavpritesh Sethi and the Center for Artificial Intelligence at IIIT-Delhi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ATLAS dataset (available for download at https://amr.theodi.org/programmes/atlas) is an open-access dataset on human AMR surveillance data generated by the commercial pharmaceutical company Pfizer that contains granular antibiotic susceptibility data made publicly available as per the DAVOS Declaration and United Nations Global Assembly Declaration in compliance with the IRB policies and detailed at https://amr.theodi.org/
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Language, figures, and tables improved.
Data Availability
Culture Sensitivity Data were obtained on registration to the Wellcome AMR Surveillance Prize. Analysis and results used in this publication were generated as part of the Wellcome Trust Data Re-use Prize: AMR Surveillance, obtained through Synapse ID syn17009517 and with support from the Open Data Institute, Pfizer, and Sage Bionetworks. Data for Worldwide Governance Indicators, Global Burden of Disease, and Global Financial Development Database are publicly available.
https://www.worldbank.org/en/publication/gfdr/data/global-financial-development-database
https://datacatalog.worldbank.org/dataset/worldwide-governance-indicators
